Cargando…

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the leading cause of severe visual loss and blindness over the age of 50 in developed countries. Vascular endothelial growth factor (VEGF) is considered as a critical molecule in the pathogenesis of choroidal neovascularization (CNV), which characterizes the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zampros, Ilias, Praidou, Anna, Brazitikos, Periklis, Ekonomidis, Panagiotis, Androudi, Sofia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228312/ https://www.ncbi.nlm.nih.gov/pubmed/22174998 http://dx.doi.org/10.1155/2012/319728

Ejemplares similares

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
por: Tranos, Paris, et al.
Publicado: (2013)

Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
por: Chandra, Shruti, et al.
Publicado: (2020)

Alexandrite Laser-Induced Choroidal Neovascularization Successfully Treated With Aflibercept
por: Diafas, Asterios, et al.
Publicado: (2020)

ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
por: Nguyen, Vuong, et al.
Publicado: (2021)

Diabetic Retinopathy Treated with Laser Photocoagulation and the Indirect Effect on Glycaemic Control
por: Praidou, Anna, et al.
Publicado: (2014)

Ocular disease awareness and pattern of ocular manifestation in patients with biopsy-proven lung sarcoidosis
por: Pefkianaki, Maria, et al.
Publicado: (2011)

Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study
por: Yang, Benjamin Chi-Lan, et al.
Publicado: (2019)

Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy
por: Chen, Yu-Yen, et al.
Publicado: (2019)

Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD
por: Kamao, Hiroyuki, et al.
Publicado: (2018)

Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis
por: Yin, Xiaobei, et al.
Publicado: (2022)

Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
por: Hujanen, Pekko, et al.
Publicado: (2023)

Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration
por: Seong, Hyo Jin, et al.
Publicado: (2022)

Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice
por: Gurung, Rajya L, et al.
Publicado: (2021)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up
por: Javidi, Simon, et al.
Publicado: (2020)

Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat‐and‐extend compared with pro re nata in eyes with neovascular age‐related macular degeneration
por: Aurell, Sandra, et al.
Publicado: (2018)

Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: A case report
por: Nagai, Norihiro, et al.
Publicado: (2017)

Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
por: Mansour, Ahmad M., et al.
Publicado: (2014)

Clinical characteristics and antivascular endothelial growth factor effect of choroidal neovascularization in younger patients in Taiwan
por: Li, Yi-Hsuan, et al.
Publicado: (2015)

Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes
por: Mun, Yongseok, et al.
Publicado: (2021)

Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases
por: Hong, In Hwan, et al.
Publicado: (2017)

The Use of Antivascular Endothelial Growth Factor Agents in the Perioperative Period in Diabetic Vitrectomy
por: Abu-Yaghi, Nakhleh E., et al.
Publicado: (2012)

Promising Novel Treatment against Keloids: Antivascular Endothelial Growth Factor Agents
por: Abtahi-Naeini, Bahareh, et al.
Publicado: (2019)

Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy
por: Delas, Barbara, et al.
Publicado: (2012)

Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration
por: Hussain, Rehan M, et al.
Publicado: (2021)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Combined argon laser photocoagulation and antivascular endothelial growth factor for management of macular polypoidal choroidal vasculopathy
por: Sen, Parveen, et al.
Publicado: (2016)

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity
por: Dudani, Ajay Indur, et al.
Publicado: (2019)

Ten-year outcome of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration
por: Upasani, Deepa, et al.
Publicado: (2021)

Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
por: Hanhart, Joel, et al.
Publicado: (2022)

Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment
por: Moon, Bo-Hyun, et al.
Publicado: (2023)

Growth of nonexudative macular neovascularization in age-related macular degeneration: an indicator of biological lesion activity
por: Wang, Yusong, et al.
Publicado: (2022)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat, Davis, et al.
Publicado: (2020)

Therapies for Neovascular Age-Related Macular Degeneration: Current Approaches and Pharmacologic Agents in Development
por: Hanout, Mostafa, et al.
Publicado: (2013)

Profiling neovascular age‐related macular degeneration choroidal neovascularization lesion response to anti‐vascular endothelial growth factor therapy using SSOCTA
por: Told, Reinhard, et al.
Publicado: (2020)

Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Kim, Jae-Hui, et al.
Publicado: (2021)

Radiation therapy for neovascular age-related macular degeneration
por: Petrarca, Robert, et al.
Publicado: (2011)

Experimental Models in Neovascular Age Related Macular Degeneration
por: Rastoin, Olivia, et al.
Publicado: (2020)

Pipeline therapies for neovascular age related macular degeneration
por: Arepalli, Sruthi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rbg0f3ipj2l8h6dm91af2qjl4a